ELDN
ELDN clinical trials: Eledon Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Eledon Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 6
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
ELDN on the catalyst calendar · ELDN registry changes
- Primary completion Mar 2029Sponsor estimatePhase 3NCT07835581Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney TransplantationEledon Pharmaceuticals · Kidney Transplant RejectionNot yet recruitingELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 11, 2025ActualPhase 2NCT05983770Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney TransplantationEledon Pharmaceuticals · Kidney Transplant RejectionCompletedELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 2NCT06126380Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant RecipientsEledon Pharmaceuticals · Kidney Transplant RejectionEnrolling by invitationELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 1/Phase 2NCT05027906Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney TransplantEledon Pharmaceuticals · Prevention of Rejection in Kidney TransplantRecruitingELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 31, 2023ActualPhase 2NCT05125068Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)Eledon Pharmaceuticals · IgA NephropathyTerminatedELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2024Sponsor estimatePhase 1/Phase 2NCT05480657Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1DEledon Pharmaceuticals · Brittle Type 1 Diabetes MellitusWithdrawnELDNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2030Sponsor estimateEarly Phase 1NCT06972069Tolerance Through Mixed Chimerism (Sip-Tego)Tatsuo Kawai, MD, PhD · Kidney FailureActive, not recruitingELDNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2029Sponsor estimatePhase 1/Phase 2NCT06305286Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet...University of Chicago · Type 1 Diabetes MellitusActive, not recruitingELDNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner